

Xilio Therapeutics, Inc.  
828 Winter Street, Suite 300  
Waltham, MA 02451

November 16, 2022

**VIA EDGAR SUBMISSION**

U.S. Securities and Exchange Commission  
Division of Corporation Finance, Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549  
Attention: Christine Westbrook

Re: Xilio Therapeutics, Inc.  
Registration Statement on Form S-3  
File No. 333-268264  
Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Xilio Therapeutics, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-268264), so that it may become effective at 4:00 p.m., Eastern time, on November 18, 2022, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.

Very truly yours,

XILIO THERAPEUTICS, INC.

By: /s/ René Russo

Name: René Russo

Title: Chief Executive Officer

---